SOLACE

Closed

ANZ 1103: SOLACE

BCT Study Chair:

Chee Lee

A phase I clinical trial for men or women with advanced breast or ovarian cancer. Phase I clinical trials test the safe dose levels of new drug therapies. The drugs which will be tested in the SOLACE study (Olaparib and cyclophosphamide) are used to treat both breast and ovarian cancer, however they have not been used in combination, therefore the benefits and side-effects of using them together are not yet known. Researchers believe that this combination of drugs may be effective, however first it must be shown that they can be given together safely. The primary aim of the SOLACE clinical trial will be to find out how these drugs should be given, how often, and at what doses they will be safe.

0

INTERNATIONAL

Total number of trial

participants internationally

32

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

3

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

SOLACE TRANSLATIONAL RESEARCH SAMPLES

A phase I study of Olaparib, a poly ADP-ribose polymerase-1 (PARP) inhibitor, in combination with metronomic cyclophosphamide in patients with metastatic BRCA-associated cancer, triple negative breast cancer or serous ovarian cancer (ACTRN12613000924752)

SOLACE PUBLICATIONS

2019

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.

Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M. British Journal of Cancer. 2019; 120(3):279-285, (epub 17 January 2019), Journal

2018

A Phase 1 Trial of Olaparib and Oral Metronomic Cyclophosphamide in Patients with Metastatic BRCA- Associated Breast / Ovarian Cancers or Non-BRCA Associated Triple-Negative Breast Cancer / High Grade Serous Ovarian Cancers. [MOGA 2018 – Poster].

Friedlander M, Scott CL, Lindeman GJ, Gibbs E, Badger HD, Paterson RJ, Macnab L, Zdenkowski N, Kwan EM, Boyle FM, Lee CK, on behalf of Breast Cancer Trials. Asia-Pacific Journal of Clinical Oncology. 2018; 14(53):59, Poster

2017

Phase I study of olaparib (O), in combination with oral cyclophosphamide (C), in patients (pts) with metastatic triple negative breast cancer (TNBC) and recurrent high grade serous ovarian cancer (OVCA).

Lee CK, Scott CL, Lindeman GJ, Gibbs E, Badger HD, Paterson RJ, Macnab L, Kwan EM, Boyle FM, Friedlander M, on behalf of the Australia and New Zealand Breast Cancer Trials Group. Journal of Clinical Oncology. 2017; 35(suppl; abst 1104).[ASCO Annual Meeting], Poster

SOLACE